The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Open accessAbstract
In vitro-transcribed mRNAs encoding physiologically important proteins have considerable potential for therapeutic applications. However, in its present form, mRNA is unfeasible for clinical use because of its labile and immunogenic nature. Here, we investigated whether incorporation of naturally modified nucleotides into transcripts would confer enhanced biological properties to mRNA. We found that mRNAs containing pseudouridines have a higher translational capacity than unmodified mRNAs when tested in mammalian cells and lysates or administered intravenously into mice at 0.015-0.15 mg/kg doses. The delivered mRNA and the encoded protein could be detected in the spleen at 1, 4, and 24 hours after the injection, where both products were at significantly higher levels when pseudouridine-containing mRNA was administered. Even at higher doses, only the unmodified mRNA was immunogenic, inducing high serum levels of interferon-alpha (IFN-alpha). These findings indicate that nucleoside modification is an effective approach to enhance stability and translational capacity of mRNA while diminishing its immunogenicity in vivo. Improved properties conferred by pseudouridine make such mRNA a promising tool for both gene replacement and vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both of the candidates are pharmacologically optimized 15,16 , N 1 -methylpseudouridine nucleoside-modified mRNAs 17 that are administered intramuscularly in a prime-boost regimen 21”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which is widely believed to be critical to the recent success of mRNA vaccines1,2,10,37,38”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein.”
From Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Substitution of chemically modified nucleotides in messenger ribonucleic acid (mRNA) enhances stability and transfection capability, and decreases immunogenicity1–3”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This can be circumvented by the incorporation of naturally occurring nucleosides and by applying stringent purification to remove double-stranded RNA contaminants (19–21).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [20]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Karikó et al. reported that mRNA with nucleoside modifications were insensitive to ribonuclease L (RNase L) degradation, did not activate TLRs and protein kinase R, which subsequently resulted in improved translational efficiency and stability, compared to unmodified mRNA (20).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Substitution of uridine with m1Ψ in mRNA significantly improves the translation efficiency and decreases innate immunogenicity (20).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, a successful approach to avoid overactivation of the innate immunity and increase translation of mRNA is the use of modified nucleosides such as methyl-pseudo uridine.29”
From Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA (2021) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two uridine analogs pseudouridine (Ψ) or 1-methyl-pseudouridine (m1Ψ) are widely used for mRNA therapeutics because they can increase mRNA stability and help modulate the host immune response31,32.”
From Human 5′ UTR design and variant effect prediction from a massively parallel translation assay (2019) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, we focused on ψ and m1ψ, since these substitutions for U have been widely adopted for mRNA therapeutics and vaccines due to improved in-cell translation and to better control of innate immune responses2,3,8,67 through avoidance of recognition by cellular toll-like receptors (TLR7 and TLR8)68, RIG‑I, and PKR69–71.”
From Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics (2022) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Replacing of uridine by pseudouridine into mRNA gives superior nonimmunogenic mRNA with increased translational capacity and biological stability (20).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Our work principally confirms that conventional unmodified mRNAs are inferior to molecules harboring specific nucleoside modifications as suggested by various recent reports,23,24,25,26,27 however, the picture changes dramatically with a sophisticated sequence-engineering.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Although pseudouridine is primarily found in tRNA, rRNA, and small nuclear RNAs, pseudouridine-containing mRNAs were still translated and produced even more protein compared to unmodified mRNA.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“As mammalian host cells attack unmodified exogeneous RNA [12,13], all U nucleotides were replaced by N1-methylpseudouridine (Ψ) [14,15].”
From Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines (2021) · cites this paper as [12]
In the citing paper
“To avoid this, Karikó and colleagues found that adding modified nucleosides during IVT of mRNA can significantly reduce the host inflammatory response without affecting protein expression.81,159”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [159]
In the citing paper
“Studies have found that replacing original nucleosides with m6A and s2U inhibits activation of TLR3, whereas activation of TLR7 and TLR8 is blocked when using ψ, 5-methyluridine (m5U), m6A, and s2U, thereby inhibiting the innate immune responses and improving protein translation efficiency.81,159,171”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [159]
In the citing paper
“However, the incorporation of modified nucleosides into mRNA can significantly improve the biological stability and translational capacity of the mRNA while decreasing the innate immune response.36, 37, 38”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [37]
In the citing paper
“These alterations possibly lead to a blunted specific immune response.37,133, 134, 135”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [37]
In the citing paper
“Nevertheless, immune responses to IVT mRNA may also suppress antigen expression and negatively affect vaccine efficacy175,180,181.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [180]
In the citing paper
“Taken together, these findings resulted in a paradigm of the design of mRNA formulations for vaccination.One strategy is to use mRNA which is fully optimized to obtain a strong adjuvant effect, another is to work with 'modified' mRNA with high translation capacity, and thus improved antigen bio-availability [43,62].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., & Fujita, T. (2004) · Nature Immunology · doi:10.1038/ni1087 · Cited by 4,022
Self-citationSpecies-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Self-citationLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Self-citationLutz, M. B., Kukutsch, N. A., Ogilvie, A. L. J., Rößner, S., Koch, F., Romani, N., & Schuler, G. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00204-x · Cited by 2,972
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citation5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Self-citationRaper, S. E., Chirmule, N. B., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,531
Flagged first, then by citations
1 of the 30 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 801–900 of 1,003
Cai, T., Atteh, L. L., Zhang, X., Huang, C., Bai, M., Ma, H., Zhang, C., Fu, W., Gao, L., Lin, Y., et al. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.819335 · Cited by 20
Making COVID-19 mRNA vaccines accessible: challenges resolved
Niazi, S. K. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2089121 · Cited by 19
Robust genome editing via modRNA-based Cas9 or base editor in human pluripotent stem cells
Haideri, T., Howells, A. R., Jiang, Y., Yang, J., Bao, X., & Lian, X. L. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100290 · Cited by 18
Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression
Zadory, M., Lopez, E., Babity, S., Gravel, S., & Brambilla, D. (2022) · Biomaterials Science · doi:10.1039/d2bm00859a · Cited by 18
Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination
Fryer, H. A., Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220415 · Cited by 16
de Moura, I. A., Silva, A. J. D., de Macêdo, L. S., Invenção, M. D. C. V., de Sousa, M. M. G., & de Freitas, A. C. (2022) · Pathogens · doi:10.3390/pathogens11121444 · Cited by 19
COVID-19-Induced Myocarditis: Pathophysiological Roles of ACE2 and Toll-like Receptors
Pannucci, P., Jefferson, S. R., Hampshire, J., Cooper, S. L., Hill, S. J., & Woolard, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065374 · Cited by 21
Jalan, A., Jayaprakash, J. P., Karemore, P., Narayan, K. P., & Khandelia, P. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00792-1 · Cited by 19
C-Ribosylating Enzymes in the (Bio)Synthesis of C-Nucleosides and C-Glycosylated Natural Products
Pfeiffer, M., & Nidetzky, B. (2023) · ACS Catalysis · doi:10.1021/acscatal.3c04436 · Cited by 20
Mahony, T. J., Briody, T. E., & Ommeh, S. C. (2024) · Vaccines · doi:10.3390/vaccines12020152 · Cited by 22
RNA-Based Vaccination: Sending a Strong Message
Weiner, D. B. (2013) · Molecular Therapy · doi:10.1038/mt.2013.26 · Cited by 19
Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies
Antony, J. S., Dewerth, A., Haque, A., Handgretinger, R., & Kormann, M. (2015) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-015-0022-6 · Cited by 18
Blanchard, E. L., Loomis, K. H., Bhosle, S. M., Vanover, D. A., Baumhof, P., Pitard, B., Zurla, C., & Santangelo, P. J. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.002 · Cited by 19
Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells
Ségaliny, A. I., Cheng, J. L., Farhoodi, H. P., Toledano, M., Yu, C. C., Tierra, B. A., Hildebrand, L., Liu, L., Liao, M. J., Cho, J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.047 · Cited by 19
Ely, A., Singh, P., Smith, T. S., & Arbuthnot, P. B. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.010 · Cited by 19
Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV
D’haese, S., Lacroix, C., García, F., Plana, M., Ruță, S. M., Vanham, G. L., Verrier, B., & Aerts, J. L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.009 · Cited by 18
Business: The billion-dollar biotech
Dolgin, E. (2015) · Nature · doi:10.1038/522026a · Cited by 19
BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2Preprint
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.11.421008 · Cited by 18
Discovery and development of COVID ‐19 vaccine from laboratory to clinic
Saravanan, V., Chagaleti, B. K., Narayanan, P. L., Anandan, V. B., Manoharan, H., Anjana, G. V., Peraman, R., Namasivayam, S. K. R., Kavisri, M., Arockiaraj, J., et al. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14383 · Cited by 19
Woodward, E., Wang, E., Wallis, C. J. D., Sharma, R. K., Tie, A. W. J., Murthy, N., & Blancafort, P. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4051-7_14 · Cited by 18
Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials
Tiwade, P. B., Fung, V., VanKeulen‐Miller, R., Narasipura, E. A., Ma, Y., & Fenton, O. S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00871 · Cited by 18
Applications of multiplexed CRISPR–Cas for genome engineering
Cheng, H., Jeong, E., & Cho, S. W. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01500-6 · Cited by 22
mRNA Vaccines: Current Applications and Future Directions
Li, J., Liu, Y., Dai, J., Li, Y., Xiong, F., Xia, J., Jin, J., Wu, Y., & Peng, X. (2025) · MedComm · doi:10.1002/mco2.70434 · Cited by 27
Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity
Parayath, N. N., Hao, S., Stephan, S. B., Koehne, A. L., Watson, C. E., & Stephan, M. T. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.040 · Cited by 18
Physical and chemical advances of synthetic delivery vehicles to enhance mRNA vaccine efficacy
Kim, H. J., Seo, S. K., & Park, H. Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.029 · Cited by 18
Nakagami, H., Hayashi, H., Sun, J., Yanagida, Y., Otera, T., Nakagami, F., Hamaguchi, S., Yoshida, H., Okuno, H., Yoshida, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10091427 · Cited by 18
Low Resource Integrated Platform for Production and Analysis of Capped mRNA
Nwokeoji, A. O., Chou, T.-C., & Nwokeoji, E. A. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00609 · Cited by 18
Gu, J., Xu, Z., Liu, Q., Tang, S., Zhang, W., Xie, S., Chen, X., Chen, J., Yong, K., Yang, C., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302409 · Cited by 20
Functional Nucleic Acid-Based Immunomodulation for T Cell-Mediated Cancer Therapy
Wu, H., Lin, J., Ling, N., Zhang, Y., He, Y., Qiu, L., & Tan, W. (2023) · ACS Nano · doi:10.1021/acsnano.3c09861 · Cited by 18
Profile of Katalin Karikó and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine
Krammer, F., & Palese, P. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2400423121 · Cited by 19
Masum, M. H. U., Wajed, S., Hossain, M. I., Moumi, N. R., Talukder, A., & Rahman, M. M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305413 · Cited by 18
Alkyne-Functionalized Coumarin Compound for Analytic and Preparative 4-Thiouridine Labeling
Schmid, K., Adobes‐Vidal, M., & Helm, M. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00035 · Cited by 18
Mineral-Coated Microparticles Enhance mRNA-Based Transfection of Human Bone Marrow Cells
Fontana, G., Martin, H. L., Lee, J. S., Schill, K., Hematti, P., & Murphy, W. L. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.09.004 · Cited by 18
Bişgin, A., Şanlioğlu, A. D., Ekşi, Y. E., Griffith, T. S., & Şanlıoğlu, S. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.052 · Cited by 18
RNA modifications act as regulators of cell death
Xu, L., Zhang, C., Yin, H., Gong, S., Wu, N., Ren, Z., & Zhang, Y. (2021) · RNA Biology · doi:10.1080/15476286.2021.1925460 · Cited by 19
Rezaei, M., & Nazari, M. (2022) · Avicenna Journal of Medical Biotechnology · doi:10.18502/ajmb.v14i1.8167 · Cited by 21
Selective hydrophobic interaction chromatography for high purity of supercoiled DNA plasmids
Božič, K., Sedlar, A., Kralj, Š., Černigoj, U., Štrancar, A., & Sekirnik, R. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28667 · Cited by 17
In vivo liver targeted genome editing as therapeutic approach: progresses and challenges
Simoni, C., Barbon, E., Muro, A. F., & Cantore, A. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1458037 · Cited by 20
mRNABERT: advancing mRNA sequence design with a universal language model and comprehensive dataset
Xiong, Y., Wang, A., Kang, Y., Shen, C., Hsieh, C., & Hou, T. (2025) · Nature Communications · doi:10.1038/s41467-025-65340-8 · Cited by 20
Navigating the next frontier in biomedicine: breakthroughs and insights in nucleic acid therapeutics
Wu, S., Zhang, Z., Zhao, Z., Cui, C., & Tan, W. (2026) · Chemical Science · doi:10.1039/d5sc06966a · Cited by 21
Nakanishi, H., Saito, H., & Itaka, K. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00567 · Cited by 17
mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People
Garbuglia, A. R., Minosse, C., & Porto, P. D. (2022) · Viruses · doi:10.3390/v14040748 · Cited by 17
Alameh, M., & Weissman, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821595-1.00014-2 · Cited by 17
Self-citationMokuda, S., Watanabe, H., Kohno, H., Ishitoku, M., Araki, K., Hirata, S., & Sugiyama, E. (2022) · Cytotechnology · doi:10.1007/s10616-022-00540-4 · Cited by 16
Transgene-free direct conversion of murine fibroblasts into functional muscle stem cells
Qabrati, X., Kim, I., Ghosh, A., Bundschuh, N., Noé, F., Palmer, A. S., & Bar‐Nur, O. (2023) · npj Regenerative Medicine · doi:10.1038/s41536-023-00317-z · Cited by 18
COVID-19 Variants and Vaccine Development
Zhao, Z., Bashiri, S., Ziora, Z. M., Tóth, I., & Skwarczyński, M. (2024) · Viruses · doi:10.3390/v16050757 · Cited by 20
Delehedde, C., Ciganek, I., Bernard, P.-L., Laroui, N., Silva, C. C. D., Gonçalves, C., Nunès, J. A., Griscelli, A. B., Imeri, J., Huyghe, M., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102263 · Cited by 18
Tadic, S., & Martı́nez, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433185 · Cited by 19
Wang, P., Logeart‐Avramoglou, D., Petite, H., Gonçalves, C., Midoux, P., Perche, F., & Pichon, C. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.03.045 · Cited by 17
COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective
Cavaillon, J.-M., & Osuchowski, M. F. (2021) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2021.04.003 · Cited by 17
Engineered mRNA and the Rise of Next-Generation Antibodies
Sanz, L., & Álvarez‐Vallina, L. (2021) · Antibodies · doi:10.3390/antib10040037 · Cited by 17
RNA-Based Strategies for Cell Reprogramming toward Pluripotency
Bailly, A., Milhavet, O., & Lemaı̂tre, J.-M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020317 · Cited by 18
Exciting Times for Lipid Nanoparticles: How Canadian Discoveries Are Enabling Gene Therapies
Cheng, M. H. Y., Brimacombe, C. A., Verbeke, R., & Cullis, P. R. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00365 · Cited by 18
Metabolic disorders affecting the liver and heart: Therapeutic efficacy of miRNA-based therapies?
Sala, L. L., Carlini, V., Conte, C., Macas-Granizo, M. B., Afzalpour, E., Martín-Delgado, J., D’Anzeo, M., Pedretti, R. F. E., Naselli, A., Pontiroli, A. E., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107083 · Cited by 18
Vaccine formulation design: challenges and opportunities
Zafar, S., Akhtar, A., Sayed, E., Onaiwu, E., Arshad, M. S., & Ahmad, Z. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00017c · Cited by 17
Determining the effects of pseudouridine incorporation on human tRNAs
Biela, A., Nowak, J. S., Biela, A. P., Mukherjee, S., Moafinejad, S. N., Maiti, S., Chramiec‐Głąbik, A., Mehta, R., Jeżowski, J., Dobosz, D., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00443-y · Cited by 16
Zhao, Y., Chen, X., Zhang, X., & Liu, H. (2025) · Biomarker Research · doi:10.1186/s40364-025-00794-y · Cited by 18
Grudzinska‐Goebel, J., Braun, M., Chen, L., Gupta, S., Lohmann, S., Morais, P., Niu, T., Tarcsa, E., Tourdot, S., Youssef, A. S., et al. (2025) · Nucleic Acid Therapeutics · doi:10.1177/21593337251387423 · Cited by 17
Kapnick, S. M. (2021) · DNA and Cell Biology · doi:10.1089/dna.2021.0538 · Cited by 16
Rcheulishvili, N., Papukashvili, D., Liu, C., Ji, Y., He, Y., & Wang, P. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1025884 · Cited by 17
Discovering glycoRNA: Traditional and Non‐Canonical Approaches to Studying RNA Modifications
Caldwell, R. M., & Flynn, R. A. (2022) · Israel Journal of Chemistry · doi:10.1002/ijch.202200059 · Cited by 16
Solodushko, V., & Fouty, B. (2023) · Gene Therapy · doi:10.1038/s41434-023-00391-4 · Cited by 18
Guo, X., Liu, D., Huang, Y., Deng, Y., Wang, Y., Mao, J., Zhou, Y., Xiong, Y., & Gao, X. (2023) · Virology Journal · doi:10.1186/s12985-023-02023-0 · Cited by 19
Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration
Kishore, R., & Magadum, A. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11020038 · Cited by 17
mRNA biotherapeutics landscape for rare genetic disorders
Iyer, V. R., Praveen Reddy., P., Kaduskar, B., Moharir, S. C., & Mishra, R. K. (2024) · Journal of Biosciences · doi:10.1007/s12038-023-00415-6 · Cited by 17
Targeting noncoding RNAs to treat atherosclerosis
Sopić, M., Vladimirov, S. S., Munjas, J., Mitić, T., Hall, I. F., Jusić, A., Ružić, D., Devaux, Y., & (https://atheronet.eu/), A. C. A. C. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16412 · Cited by 17
Advancement in the development of mRNA ‐based vaccines for respiratory viruses
Troncoso‐Bravo, T., Ramírez, M. A., Loaiza, R. A., Román-Cárdenas, C., Papazisis, G., Garrido, D. A., González, P. A., Bueno, S. M., & Kalergis, A. M. (2024) · Immunology · doi:10.1111/imm.13844 · Cited by 20
Dutta, N., Deb, I., Sarzyńska, J., & Lahiri, A. (2025) · ChemistrySelect · doi:10.1002/slct.202400006 · Cited by 17
Variable presence of 5-methylcytosine in commercial RNA and DNA
Schmid, K., Thüring, K. L., Keller, P., Ochel, A., Kellner, S. M., & Helm, M. (2015) · RNA Biology · doi:10.1080/15476286.2015.1076612 · Cited by 16
Messenger RNA as a Novel Therapeutic Approach
Stanton, M. G., & Murphy-Benenato, K. E. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_30 · Cited by 16
Hochmann, S., Mittermeir, M., Santic, R., Koszik, F., Griessner, L., Sonderegger, A., Hoffmann, T., Russe, E., Scheiblhofer, S., Weiss, R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31061-w · Cited by 15
Multifaceted regulation of translation by the epitranscriptomic modification N6-methyladenosine
Liu, X., & Zhou, J. L. (2021) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2020.1869174 · Cited by 16
Therapeutic Mechanism of Nucleic Acid Drugs
Liu, L., Gao, H., Guo, C., Liu, T., Li, N., & Qian, Q. (2021) · ChemistrySelect · doi:10.1002/slct.202002901 · Cited by 16
Hui, A., Li, J., Zhu, L., Tang, R., Ye, H., Lin, M., Ge, L., Wang, X., Peng, F., Wu, Z., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100586 · Cited by 19
mRNA Treatment Rescues Niemann–Pick Disease Type C1 in Patient Fibroblasts
Furtado, D. L., Cortez‐Jugo, C., Hung, Y. H., Bush, A. I., & Caruso, F. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00463 · Cited by 16
Immune-mediated liver injury following COVID-19 vaccination
Schinas, G., Polyzou, E., Dimakopoulou, V., Tsoupra, S., Gogos, C. A., & Akinosoglou, K. (2023) · World Journal of Virology · doi:10.5501/wjv.v12.i2.100 · Cited by 17
Jády, B. E., Ketele, A., Moulis, D., & Kiss, T. (2021) · Genes & Development · doi:10.1101/gad.349072.121 · Cited by 16
Viral and nonviral nanocarriers for in vivo CRISPR-based gene editing
Guo, Z., Zhu, A. T., Fang, R. H., & Zhang, L. (2024) · Nano Research · doi:10.1007/s12274-024-6748-5 · Cited by 18
LINE-1 RNA triggers matrix formation in bone cells via a PKR-mediated inflammatory response
Mangiavacchi, A., Morelli, G., Reppe, S., Saera-Vila, A., Liu, P., Eggerschwiler, B., Zhang, H., Bensaddek, D., Casanova, E. A., Medina‐Gómez, C., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00143-z · Cited by 16
Advanced reactivity-based sequencing methods for mRNA epitranscriptome profiling
Cai, Z., Song, P., Yu, K., & Jia, G. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00215f · Cited by 14
Exploring the therapeutic potential of modulating nonsense-mediated mRNA decay
McMahon, M., & Maquat, L. E. (2024) · RNA · doi:10.1261/rna.080334.124 · Cited by 16
Wang, S., Zheng, J., Zhou, J., Jiang, W., Chen, Z., Wu, X., Guo, B., Wu, Y., & Yang, F. H. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102107 · Cited by 18
Artificial intelligence for nanomedicine
Song, X., Gao, X., Wang, H., Yu, F., Qin, M., Li, Y., Liu, Y., Feng, W., Zhou, C., Chukavin, N. N., et al. (2025) · Science China Chemistry · doi:10.1007/s11426-025-2942-5 · Cited by 16
CRISPR delivery systems for organ-specific targeting: Advances and challenges
Du, J., Wu, Q., Liu, C., Wang, N., & Gong, C. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100048 · Cited by 20
Moore, S. T., Lian, X., Vaidya, A., Chatterjee, S., Santelli, J., Sun, Y., Farbiak, L., Zhu, H., & Siegwart, D. J. (2026) · Nature Communications · doi:10.1038/s41467-025-68103-7 · Cited by 16
Vaccines Against COVID-19: A Review
Torres-Estrella, C. U., Reyes-Montes, M. D. R., Duarte-Escalante, E., Sierra-Martínez, M., León, M. G. F.-D., & Acosta‐Altamirano, G. (2022) · Vaccines · doi:10.3390/vaccines10030414 · Cited by 18
The Impact of mRNA Technology in Regenerative Therapy: Lessons for Oral Tissue Regeneration
Wisitrasameewong, W., Champaiboon, C., Surisaeng, T., Sa‐Ard‐Iam, N., Freire, M., Pardi, N., Pichyangkul, S., & Mahanonda, R. (2022) · Journal of Dental Research · doi:10.1177/00220345221084205 · Cited by 15
Virus-Derived Small RNAs and microRNAs in Health and Disease
Gouzouasis, V., Tastsoglou, S., Giannakakis, A., & Hatzigeorgiou, A. G. (2023) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-122220-111429 · Cited by 14
Benčić, P., Keppler, M., Kuge, M., Qiu, D., Schütte, L. M., Häner, M., Strack, K., Jessen, H. J., Andexer, J. N., & Loenarz, C. (2023) · FEBS Journal · doi:10.1111/febs.16889 · Cited by 15
Fulfilling the Promise of RNA Therapies for Cardiac Repair and Regeneration
Giacca, M. (2023) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szad038 · Cited by 15
Making the Next Generation of Therapeutics: mRNA Meets Synthetic Biology
Hınçer, A., Ahan, R. E., Aras, E., & Şeker, U. Ö. Ş. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00253 · Cited by 15
RNA vaccines: A transformational advance
Brown, B. D., Fauci, A. S., Belkaid, Y., & Mérad, M. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.009 · Cited by 15
Recent Advances in Arboviral Vaccines: Emerging Platforms and Promising Innovations
Pujhari, S. K. (2023) · Biologics · doi:10.3390/biologics4010001 · Cited by 15
Phosphorothioate RNA Analysis by NETD Tandem Mass Spectrometry
Peters-Clarke, T. M., Quan, Q., Anderson, B. J., McGee, W. M., Lohr, E., Hebert, A. S., Westphall, M. S., & Coon, J. J. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100742 · Cited by 15
The mRNA vaccine platform for veterinary species
Fazel, F., Doost, J. S., Raj, S., Boodhoo, N., Karimi, K., & Sharif, S. (2024) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2024.110803 · Cited by 19
Chemo-enzymatic production of base-modified ATP analogues for polyadenylation of RNA
Mitton-Fry, R. M., Eschenbach, J., Schepers, H., Rasche, R., Erguven, M., Kümmel, D., Rentmeister, A., & Cornelissen, N. V. (2024) · Chemical Science · doi:10.1039/d4sc03769c · Cited by 15
Quantitative Proteomics Identifies Profilin-1 as a Pseudouridine-Binding Protein
Wei, S., Dai, X., Yuan, J. J., He, S., Shah, K., Guo, S., Duan, Z., Murn, J., & Wang, Y. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c17659 · Cited by 15
Epitranscriptome machinery in Trypanosomatids: New players on the table?
Maran, S. R., Pitta, J. L. D. L. P., Vasconcelos, C. R. D. S., McDermott, S. M., Rezende, A. M., & Moretti, N. S. (2021) · Molecular Microbiology · doi:10.1111/mmi.14688 · Cited by 13
The patent maze of COVID 19 vaccines
Storz, U. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1945581 · Cited by 14
Immunology of SARS-CoV-2 infections and vaccines
Schenten, D., & Bhattacharya, D. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.08.002 · Cited by 14
Metadata
- Authors
- Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D.
- Affiliations
- University of Pennsylvania (US)
- Rockefeller University (US)
- Research Institute for Microbial Diseases, The University of Osaka (JP)
- Corresponding author
- Karikó, Katalin
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-11
- Volume
- 16
- Issue
- 11
- Pages
- 1833-1840
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC2775451
- OpenAlex
- W2058647478
- Cited by
- 1,930
- References
- 30
- Citations by year
- 2026: 249 · 2025: 304 · 2024: 279 · 2023: 249 · 2022: 233 · 2021: 227 · 2020: 97 · 2019: 57 · 2018: 58 · 2017: 40 · 2016: 39 · 2015: 37 · 2014: 17 · 2013: 22 · 2012: 11
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health
- University of California, Riverside
- National Heart, Lung, and Blood Institute (R42HL087688, HL87688)
- National Institute of Allergy and Infectious Diseases (R01AI050484, AI050484)
- National Institute of Neurological Disorders and Stroke (NS29331, R01NS029331)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- pseudouridine, mRNA modification, nucleoside modification, in vitro transcribed mRNA, interferon-alpha, mRNA stability, translational capacity, mRNA vaccines, gene replacement therapy, intravenous delivery
- MeSH terms
- Animals, Cell Line, Genetic Vectors, Humans, Luciferases, Pseudouridine, RNA, Messenger, Transcription, Genetic, Protein Biosynthesis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
